90041-85-3

Upstream product

• 90041-46-6 Acetic acid (3aR,7aS)-5-oxo-octahydro-inden-1-yl ester 
• 90041-58-0 (3aR,4R,6aS)-4-((E)-(R)-3-Cyclohexyl-3-hydroxy-propenyl)-hexahydro-pentalen-1-one 
• 90041-58-0 (3aR,4R,6aS)-4-((E)-(S)-3-Cyclohexyl-3-hydroxy-propenyl)-hexahydro-pentalen-1-one 
• 90041-77-3 5-[(3aR,4R,6aS)-4-[(E)-(S)-3-(tert-Butyl-dimethyl-silanyloxy)-3-cyclohexyl-propenyl]-1-oxo-hexahydro-pentalen-(2E)-ylidene]-pentanoic acid methyl ester 
• 90041-53-5 (3aR,4R,6aS)-4-[(E)-(S)-3-(tert-Butyl-dimethyl-silanyloxy)-3-cyclohexyl-propenyl]-hexahydro-pentalen-1-one 
• 90041-47-7 bicyclo<3,3,0>octanecarboxylic acid 
• 84943-87-3 (3aS,6aS)-4-Oxo-octahydro-pentalene-1-carboxylic acid methyl ester 
• 68997-96-6 hydrindanone 
• 90041-49-9 C₁₁H₁₈O₃ 
• 6026-86-4 methyl 4-formylbutanoate 
• 930-30-3 cyclopent-2-enone 
• 90041-85-3 5-[(3aR,4R,6aS)-4-((E)-(S)-3-Cyclohexyl-3-hydroxy-propenyl)-1-oxo-hexahydro-pentalen-(2E)-ylidene]-pentanoic acid methyl ester 
• 90041-53-5 (3aR,4R,6aS)-4-[(E)-(R)-3-(tert-Butyl-dimethyl-silanyloxy)-3-cyclohexyl-propenyl]-hexahydro-pentalen-1-one 
• 90041-77-3 5-[(3aR,4R,6aS)-4-[(E)-(R)-3-(tert-Butyl-dimethyl-silanyloxy)-3-cyclohexyl-propenyl]-1-oxo-hexahydro-pentalen-(2E)-ylidene]-pentanoic acid methyl ester 

Downstream Products

• 90041-86-4 5-[(3aR,4R,6aS)-4-((E)-(R)-3-Cyclohexyl-3-hydroxy-propenyl)-1-oxo-hexahydro-pentalen-(2E)-ylidene]-pentanoic acid 
• 90041-86-4 5-[(3aR,4R,6aS)-4-((E)-(S)-3-Cyclohexyl-3-hydroxy-propenyl)-1-oxo-hexahydro-pentalen-(2E)-ylidene]-pentanoic acid 
• 90041-85-3 5-[(3aR,4R,6aS)-4-((E)-(S)-3-Cyclohexyl-3-hydroxy-propenyl)-1-oxo-hexahydro-pentalen-(2Z)-ylidene]-pentanoic acid methyl ester 

Relevant academic research and scientific papers

SYNTHESIS OF NEW STABLE ANALOGUES OF PROSTACYCLIN: (+/-)-6a-oxo-6,9-METHANO-l5-HYDROXYPROSTA-5,13-DIENOIC ACIDS

The synthesis is described of (+/-)-6a-oxo-6,9-methano-15-hydroxyprosta-5,13-dienoic acids as stable analogues of prostacyclin with blood platelet aggregation inhibitig activity.